# NAION

Type: Company

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/naion
Canonical HTML page: https://getlegalbrief.com/entity/naion

## Timeline

- **2026-09-22**: Civil lawsuit against Novo Nordisk reported — The Wall Street Journal reported a civil lawsuit filed against Novo Nordisk by patients who developed NAION after taking Wegovy or Ozempic; similar cases against Eli Lilly are pending.
- **2025**: AAO issues statement on GLP-1s and vision loss — The American Academy of Ophthalmology released a news release urging clinicians and patients to make informed choices about GLP-1 use after studies linked the drugs to vision loss.
- **2025**: First NAION lawsuits filed against GLP-1 makers in New Jersey — Patients begin filing lawsuits alleging that GLP-1 drugs such as Ozempic, Wegovy, and Zepbound caused permanent vision loss and that manufacturers failed to warn about the risk.
- **2024**: Boston medical center issues safety alert — Researchers at a Boston medical facility sent a safety alert flagging a possible connection between GLP-1 medications and NAION.

## Recent coverage (2 stories)

### Nearly 100 GLP-1 Vision Loss Suits in NJ Hinge on Causation Evidence
2026-09-24 00:14:01 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Nearly 100 NAION lawsuits against Novo Nordisk and Eli Lilly test pharmaceutical failure-to-warn liability. Mixed epidemiological evidence and diabetes-related blindness risk create a dense causation battleground for mass tort litigators.
Full story: https://getlegalbrief.com/story/glp-1-naion-vision-loss-lawsuits-legal

### Nearly 1,000 GLP-1 Lawsuits Allege Failure-to-Warn Vision Loss
2026-09-24 00:07:00 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Mass tort litigation against Novo Nordisk and Eli Lilly is escalating, with nearly 1,000 cases in New Jersey alone alleging the companies failed to warn patients about NAION risk.
Full story: https://getlegalbrief.com/story/glp-1-naion-vision-loss-mass-tort-litigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.